Mikolasevic Ivana, Milic Sandra, Racki Sanjin, Zaputovic Luka, Stimac Davor, Radic Mladen, Markic Dean, Orlic Lidija
Department of Nephrology, Dialysis and Kidney Transplantation, UHC Rijeka, Croatia Department of Gastroenterology, UHC Rijeka, Croatia
Department of Gastroenterology, UHC Rijeka, Croatia.
Perit Dial Int. 2016 Jul-Aug;36(4):427-32. doi: 10.3747/pdi.2014.00223. Epub 2015 Oct 16.
♦
Recent investigations indicated that nonalcoholic fatty liver disease (NAFLD), a hepatic component of metabolic syndrome (MS), is associated with an increased risk of cardiovascular disease (CVD). Accordingly, we were interested in exploring the frequency of NAFLD in peritoneal dialysis (PD) patients and analyzing factors in PD patients associated with NAFLD occurrence. In addition, we were interested in investigating whether NAFLD is associated with higher CVD risk in our PD patients. ♦
In the present cross-sectional study, we analyzed 58 PD patients. The controlled attenuation parameter (CAP) was used to detect and quantify liver steatosis with the help of transient elastography (TE) (FibroScan, Echosense SA, Paris, France). A carotid ultrasound was performed in all patients to measure carotid intimae media thickness (IMT) and plaque as surrogate measures of increased CVD risk, and we investigated their association with NAFLD. ♦
Nonalcoholic fatty liver disease was present in 74.1% of PD patients. Peritoneal dialysis/nonalcoholic fatty liver disease patients had statistically greater daily (136.5 ± 62.6 vs 93.6 ± 36.1; p = 0.02) and monthly (4,095.3 ± 1,877.7 vs 2,806.6 ± 1,083.2; p = 0.02) glucose load in comparison to the non-NAFLD/PD patients. In the next step, we were interested in analyzing what demographic and clinical characteristics in our PD patients are associated with a higher NAFLD occurrence. Presence of diabetes mellitus (DM), arterial hypertension (AH), dyslipidemia, body mass index > 25 kg/m(2), and daily glucose load > 100 g were associated with NAFLD occurrence. Peritoneal dialysis patients with NAFLD showed more carotid atherosclerosis than PD patients without NAFLD. In addition, CAP values (as indicator of liver steatosis) showed strong positive association with IMT (r = 0.801; p < 0.0001). Nonalcoholic fatty liver disease was a strong predictor of carotid atherosclerosis in PD patients. ♦
Nonalcoholic fatty liver disease is highly prevalent in PD patients. Peritoneal dialysis patients with NAFLD are at high risk of atherosclerosis. Assessment of NAFLD in PD patients may be helpful for CVD risk stratification.
♦
最近的研究表明,非酒精性脂肪性肝病(NAFLD)作为代谢综合征(MS)的肝脏组成部分,与心血管疾病(CVD)风险增加相关。因此,我们有兴趣探讨腹膜透析(PD)患者中NAFLD的发生率,并分析PD患者中与NAFLD发生相关的因素。此外,我们还想研究NAFLD是否与我们PD患者中较高的CVD风险相关。♦
在本横断面研究中,我们分析了58例PD患者。使用受控衰减参数(CAP)借助瞬时弹性成像(TE)(FibroScan, Echosense SA, 法国巴黎)检测和量化肝脏脂肪变性。对所有患者进行颈动脉超声检查,以测量颈动脉内膜中层厚度(IMT)和斑块,作为CVD风险增加的替代指标,并研究它们与NAFLD的关联。♦
74.1%的PD患者存在非酒精性脂肪性肝病。与非NAFLD/PD患者相比,腹膜透析/非酒精性脂肪性肝病患者的每日(136.5±62.6 vs 93.6±36.1;p = 0.02)和每月(4095.3±1877.7 vs 2806.6±1083.2;p = 0.02)葡萄糖负荷在统计学上更高。下一步,我们有兴趣分析我们PD患者的哪些人口统计学和临床特征与更高的NAFLD发生率相关。糖尿病(DM)、动脉高血压(AH)、血脂异常、体重指数>25 kg/m²和每日葡萄糖负荷>100 g与NAFLD的发生相关。患有NAFLD的腹膜透析患者比未患有NAFLD的PD患者表现出更多的颈动脉粥样硬化。此外,CAP值(作为肝脏脂肪变性的指标)与IMT呈强正相关(r = 0.801;p < 0.0001)。非酒精性脂肪性肝病是PD患者颈动脉粥样硬化的强预测指标。♦
非酒精性脂肪性肝病在PD患者中非常普遍。患有NAFLD的腹膜透析患者有很高的动脉粥样硬化风险。评估PD患者的NAFLD可能有助于进行CVD风险分层。